The term non-steroidal, common from around 1960, distinguishes these drugs from
corticosteroids, another class of anti-inflammatory drugs,[7] which during the 1950s had acquired a bad reputation due to overuse and side-effect problems after their introduction in 1948.[8][9][10]
There are two general types of NSAIDs available: non-selective and
COX-2 selective.[11] Most NSAIDs are non-selective, and inhibit the activity of both COX-1 and COX-2. These NSAIDs, while reducing inflammation, also inhibit platelet aggregation and increase the risk of
gastrointestinal ulcers and bleeds.[11] COX-2 selective inhibitors have fewer gastrointestinal side effects, but promote
thrombosis, and some of these agents substantially increase the risk of heart attack. As a result, certain COX-2 selective inhibitors—such as
rofecoxib—are no longer used due to the high risk of undiagnosed
vascular disease.[11] These differential effects are due to the different roles and tissue localisations of each COX isoenzyme.[11] By inhibiting physiological COX activity, NSAIDs may cause deleterious effects on kidney function,[12] and, perhaps as a result of water and sodium retention and decreases in renal blood flow, may lead to heart problems.[13] In addition, NSAIDs can blunt the production of
erythropoietin, resulting in anaemia, since haemoglobin needs this hormone to be produced.
The most prominent NSAIDs are
aspirin,
ibuprofen, and
naproxen; all available
over the counter (OTC) in most countries.[14]Paracetamol (acetaminophen) is generally not considered an NSAID because it has only minor anti-inflammatory activity. Paracetamol treats pain mainly by blocking COX-2 and inhibiting
endocannabinoid reuptake almost exclusively within the brain, and only minimally in the rest of the body.[15][16]
Medical uses
NSAIDs are often suggested for the treatment of acute or chronic conditions where
pain and inflammation are present. NSAIDs are generally used for the symptomatic relief of the following conditions:[17][18][19]
The effectiveness of NSAIDs for treating non-cancer chronic pain and cancer-related pain in children and adolescents is not clear.[27][28] There have not been sufficient numbers of high-quality randomised controlled trials conducted.[27][28]
Inflammation
Differences in anti-inflammatory activity between the various individual NSAIDs are small, but there is considerable variation among individual patients in therapeutic response and tolerance to these drugs. About 60% of patients will respond to any NSAID; of the others, those who do not respond to one may well respond to another. Pain relief starts soon after taking the first dose, and a full analgesic effect should normally be obtained within a week, whereas an anti-inflammatory effect may not be achieved (or may not be clinically assessable) for up to three weeks. If appropriate responses are not obtained within these times, another NSAID should be tried.[3]
Surgical pain
Pain following
surgery can be significant, and many people require strong pain medications such as opioids. There is some low-certainty evidence that starting NSAID painkiller medications in adults early, before surgery, may help reduce post-operative pain, and also reduce the dose or quantity of opioid medications required after surgery.[29] Any increase risk of surgical bleeding, bleeding in the gastrointestinal system, myocardial infarctions, or injury to the kidneys has not been well studied.[29] When used in combination with paracetamol, the analgesic effect on post-operative pain may be improved.[30]
Aspirin
Aspirin, the only NSAID able to irreversibly inhibit
COX-1, is also indicated for
antithrombosis through
inhibition of platelet aggregation. This is useful for the management of arterial
thrombosis, and prevention of adverse cardiovascular events like heart attacks. Aspirin inhibits platelet aggregation by inhibiting the action of
thromboxane A2.[31]
Dentistry
NSAIDs are useful in the management of post-operative
dental pain following invasive dental procedures such as
dental extraction. When not contra-indicated, they are favoured over the use of
paracetamol alone due to the anti-inflammatory effect they provide.[32] There is weak evidence suggesting that taking pre-operative analgesia can reduce the length of post operative pain associated with placing orthodontic spacers under local anaesthetic.[33]
The widespread use of NSAIDs has meant that the adverse effects of these drugs have become increasingly common. Use of NSAIDs increases risk of a range of
gastrointestinal (GI) problems, kidney disease and adverse cardiovascular events.[40][41] As commonly used for post-operative pain, there is evidence of increased risk of kidney complications.[42] Their use following gastrointestinal surgery remains controversial, given mixed evidence of increased risk of leakage from any bowel
anastomosis created.[43][44][45]
An estimated 10–20% of people taking NSAIDs experience
indigestion. In the 1990s high doses of prescription NSAIDs were associated with serious upper gastrointestinal adverse events, including bleeding.[46]
NSAIDs, like all medications, may interact with other medications. For example, concurrent use of NSAIDs and
quinolone antibiotics may increase the risk of quinolones' adverse
central nervous system effects, including seizure.[47][48]
There is an argument over the benefits and risks of NSAIDs for treating chronic musculoskeletal pain. Each drug has a benefit-risk profile and balancing the risk of no treatment with the competing potential risks of various therapies should be considered.[49] For people over the age of 65 years old, the balance between the benefits of pain-relief medications such as NSAIDS and the potential for adverse effects has not been well determined.[50]
There is some evidence suggesting that, for some people, use of NSAIDs (or other anti-inflammatories) may contribute to the initiation of chronic pain.[51]
Side effects are dose-dependent, and in many cases severe enough to pose the risk of ulcer perforation, upper gastrointestinal bleeding, and death, limiting the use of NSAID therapy. An estimated 10-20% of NSAID patient's experience
dyspepsia, and NSAID-associated upper gastrointestinal adverse events are estimated to result in 103,000 hospitalizations and 16,500 deaths per year in the United States, and represent 43% of drug-related emergency visits. Many of these events are avoidable; a review of physician visits and prescriptions estimated that unnecessary prescriptions for NSAIDs were written in 42% of visits.[52]
Aspirin should not be taken by people who have
salicylate intolerance[53][54] or a more generalized
drug intolerance to NSAIDs, and caution should be exercised in those with
asthma or
NSAID-precipitated
bronchospasm. Owing to its effect on the stomach lining, manufacturers recommend people with
peptic ulcers, mild
diabetes, or
gastritis seek medical advice before using aspirin.[55][56] Use of aspirin during
dengue fever is not recommended owing to increased bleeding tendency.[57] People with
kidney disease,
hyperuricemia, or
gout should not take aspirin because it inhibits the kidneys' ability to excrete
uric acid, and thus may exacerbate these conditions.
Combinational risk
If a
COX-2 inhibitor is taken, a traditional NSAID (prescription or over-the-counter) should not be taken at the same time.[58]
Rofecoxib (Vioxx) was shown to produce significantly fewer gastrointestinal adverse drug reactions (
ADRs) compared with naproxen.[59] The study, the VIGOR trial, raised the issue of the cardiovascular safety of the coxibs (COX-2 inhibitors). A statistically significant increase in the incidence of
myocardial infarctions was observed in patients on rofecoxib. Further data, from the APPROVe trial, showed a statistically significant relative risk of cardiovascular events of 1.97 versus placebo[60]—which caused a worldwide withdrawal of rofecoxib in October 2004.[61]
Use of methotrexate together with NSAIDs in
rheumatoid arthritis is safe, if adequate monitoring is done.[62]
Cardiovascular
NSAIDs, aside from aspirin, increase the risk of
myocardial infarction and
stroke.[63][64] This occurs at least within a week of use.[5] They are not recommended in those who have had a previous heart attack as they increase the risk of death or recurrent MI.[65] Evidence indicates that
naproxen may be the least harmful out of these.[64][66]
NSAIDs aside from (low-dose) aspirin are associated with a doubled risk of
heart failure in people without a history of cardiac disease.[66] In people with such a history, use of NSAIDs (aside from low-dose aspirin) was associated with a more than 10-fold increase in heart failure.[67] If this link is proven causal, researchers estimate that NSAIDs would be responsible for up to 20 percent of hospital admissions for congestive heart failure. In people with heart failure, NSAIDs increase mortality risk (
hazard ratio) by approximately 1.2–1.3 for naproxen and ibuprofen, 1.7 for rofecoxib and celecoxib, and 2.1 for diclofenac.[68]
A 2005 Finnish survey study found an association between long term (over three months) use of NSAIDs and
erectile dysfunction.[70]
A 2011 publication[71] in The Journal of Urology received widespread publicity.[72] According to the study, men who used NSAIDs regularly were at significantly increased risk of erectile dysfunction. A link between NSAID use and erectile dysfunction still existed after controlling for several conditions. However, the study was observational and not controlled, with low original participation rate, potential participation bias, and other uncontrolled factors. The authors warned against drawing any conclusion regarding cause.[73]
Gastrointestinal
The main
adverse drug reactions (ADRs) associated with NSAID use relate to direct and indirect irritation of the
gastrointestinal (GI) tract. NSAIDs cause a dual assault on the GI tract: the acidic molecules directly irritate the
gastric mucosa, and inhibition of COX-1 and COX-2 reduces the levels of protective
prostaglandins.[40] Inhibition of prostaglandin synthesis in the GI tract causes increased gastric acid secretion, diminished bicarbonate secretion, diminished mucus secretion and diminished trophic effects on the epithelial mucosa.[74]
Clinical NSAID ulcers are related to the systemic effects of NSAID administration. Such damage occurs irrespective of the route of administration of the NSAID (e.g., oral, rectal, or parenteral) and can occur even in people who have
achlorhydria.[76]
Ulceration risk increases with therapy duration, and with higher doses. To minimize GI side effects, it is prudent to use the lowest effective dose for the shortest period of time—a practice that studies show is often not followed. Over 50% of patients who take NSAIDs have sustained some mucosal damage to their small intestine.[77]
The risk and rate of gastric adverse effects is different depending on the type of NSAID medication a person is taking.
Indomethacin,
ketoprofen, and
piroxicam use appear to lead to the highest rate of gastric adverse effects, while
ibuprofen (lower doses) and
diclofenac appear to have lower rates.[17]
Certain NSAIDs, such as aspirin, have been marketed in
enteric-coated formulations that manufacturers claim reduce the incidence of gastrointestinal ADRs. Similarly, some believe that rectal formulations may reduce gastrointestinal ADRs. However, consistent with the systemic mechanism of such ADRs, and in clinical practice, these formulations have not demonstrated a reduced risk of GI ulceration.[17]
Numerous "gastro-protective" drugs have been developed with the goal of preventing gastrointestinal toxicity in people who need to take NSAIDs on a regular basis.[40] Gastric adverse effects may be reduced by taking medications that suppress acid production such as
proton pump inhibitors (e.g.:
omeprazole and
esomeprazole), or by treatment with a drug that mimics
prostaglandin in order to restore the lining of the GI tract (e.g.: a prostaglandin analog
misoprostol).[40] Diarrhea is a common side effect of misoprostol; however, higher doses of misoprostol have been shown to reduce the risk of a person having a complication related to a gastric ulcer while taking NSAIDs.[40] While these techniques may be effective, they are expensive for maintenance therapy.[78]
Hydrogen sulfide NSAID hybrids prevent the gastric ulceration/bleeding associated with taking the NSAIDs alone. Hydrogen sulfide is known to have a protective effect on the cardiovascular and gastrointestinal system.[79]
NSAIDs are also associated with a fairly high incidence of adverse drug reactions (
ADRs) on the kidney and over time can lead to
chronic kidney disease. The mechanism of these kidney ADRs is due to changes in kidney blood flow. Prostaglandins normally dilate the
afferent arterioles of the
glomeruli. This helps maintain normal glomerular perfusion and
glomerular filtration rate (GFR), an indicator of
kidney function. This is particularly important in kidney failure where the kidney is trying to maintain renal perfusion pressure by elevated angiotensin II levels. At these elevated levels, angiotensin II also constricts the afferent arteriole into the glomerulus in addition to the efferent arteriole it normally constricts. Since NSAIDs block this prostaglandin-mediated effect of afferent arteriole dilation, particularly in kidney failure, NSAIDs cause unopposed constriction of the afferent arteriole and decreased RPF (renal perfusion flow) and GFR.[81]
Common ADRs associated with altered kidney function include:[17]
These agents may also cause kidney impairment, especially in combination with other nephrotoxic agents. Kidney failure is especially a risk if the patient is also concomitantly taking an
ACE inhibitor (which removes angiotensin II's vasoconstriction of the efferent arteriole) and a
diuretic (which drops plasma volume, and thereby RPF)—the so-called "triple whammy" effect.[82]
In rarer instances NSAIDs may also cause more severe kidney conditions:[17]
Photosensitivity is a commonly overlooked adverse effect of many of the NSAIDs.[84] The 2-arylpropionic acids are the most likely to produce photosensitivity reactions, but other NSAIDs have also been implicated including
piroxicam,
diclofenac, and
benzydamine.[85]
Benoxaprofen, since withdrawn due to its
liver toxicity, was the most photoactive NSAID observed. The mechanism of photosensitivity, responsible for the high photoactivity of the 2-arylpropionic acids, is the ready
decarboxylation of the
carboxylic acidmoiety. The specific absorbance characteristics of the different
chromophoric 2-aryl substituents, affects the decarboxylation mechanism.[86]
During pregnancy
While NSAIDs as a class are not direct
teratogens, use of NSAIDs in late pregnancy can cause premature closure of the fetal
ductus arteriosus and kidney ADRs in the fetus.[87] Thus, NSAIDs are not recommended during the third trimester of pregnancy because of the increased risk of premature constriction of the ductus arteriosus.[87] Additionally, they are linked with
premature birth[88] and
miscarriage.[89] Aspirin, however, is used together with
heparin in pregnant women with
antiphospholipid syndrome.[90] Additionally,
indomethacin can be used in pregnancy to treat
polyhydramnios by reducing fetal urine production via inhibiting fetal renal blood flow.[91]
In contrast,
paracetamol (acetaminophen) is regarded as being safe and well tolerated during pregnancy, but Leffers et al. released a study in 2010, indicating that there may be associated male infertility in the unborn.[92][93] Doses should be taken as prescribed, due to risk of liver toxicity with overdoses.[94]
In France, the country's health agency contraindicates the use of NSAIDs, including aspirin, after the sixth month of pregnancy.[95]
In October 2020, the U.S.
Food and Drug Administration (FDA) required the
drug label to be updated for all nonsteroidal anti-inflammatory medications to describe the risk of kidney problems in unborn babies that result in low amniotic fluid.[96][97] They are recommending avoiding NSAIDs in pregnant women at 20 weeks or later in pregnancy.[96][97]
Allergy and allergy-like hypersensitivity reactions
A variety of allergic or allergic-like
NSAID hypersensitivity reactions follow the ingestion of NSAIDs. These hypersensitivity reactions differ from the other adverse reactions listed here which are toxicity reactions, i.e. unwanted reactions that result from the pharmacological action of a drug, are dose-related, and can occur in any treated individual; hypersensitivity reactions are idiosyncratic reactions to a drug.[98] Some NSAID hypersensitivity reactions are truly allergic in origin: 1) repetitive
IgE-mediated
urticarial skin eruptions,
angioedema, and
anaphylaxis following immediately to hours after ingesting one structural type of NSAID but not after ingesting structurally unrelated NSAIDs; and 2) Comparatively mild to moderately severe
T cell-mediated delayed onset (usually more than 24 hour), skin reactions such as
maculopapular rash,
fixed drug eruptions,
photosensitivity reactions, delayed
urticaria, and
contact dermatitis; or 3) far more severe and potentially life-threatening t-cell-mediated delayed systemic reactions such as the
DRESS syndrome,
acute generalized exanthematous pustulosis, the
Stevens–Johnson syndrome, and
toxic epidermal necrolysis. Other NSAID hypersensitivity reactions are allergy-like symptoms but do not involve true allergic mechanisms; rather, they appear due to the ability of NSAIDs to alter the metabolism of arachidonic acid in favor of forming metabolites that promote allergic symptoms. Affected individuals may be abnormally sensitive to these provocative metabolites or overproduce them and typically are susceptible to a wide range of structurally dissimilar NSAIDs, particularly those that inhibit COX1. Symptoms, which develop immediately to hours after ingesting any of various NSAIDs that inhibit COX-1, are: 1) exacerbations of asthmatic and rhinitis (see
aspirin-exacerbated respiratory disease) symptoms in individuals with a history of
asthma or
rhinitis and 2) exacerbation or first-time development of
wheals or
angioedema in individuals with or without a history of chronic
urticarial lesions or angioedema.[39]
Possible effects on bone and soft tissue healing
It has been hypothesized that NSAIDs may delay healing from
bone and
soft-tissue injuries by inhibiting inflammation.[99] On the other hand, it has also been hypothesized that NSAIDs might speed recovery from soft tissue injuries by preventing inflammatory processes from damaging adjacent, non-injured muscles.[100]
There is moderate evidence that they delay bone healing.[101] Their overall effect on soft-tissue healing is unclear.[100][99][102]
Ototoxicity
Long-term use of NSAID analgesics and paracetamol is associated with an increased risk of hearing loss.[103][104][105]
Other
The use of NSAIDs for analgesia following gastrointestinal surgery remains controversial, given mixed evidence of an increased risk of leakage from any bowel
anastomosis created. This risk may vary according to the class of NSAID prescribed.[43][44][45]
Most NSAIDs penetrate poorly into the
central nervous system (CNS). However, the COX enzymes are expressed constitutively in some areas of the CNS, meaning that even limited penetration may cause adverse effects such as somnolence and dizziness.[107]
NSAIDs may increase the risk of bleeding in patients with
Dengue fever[108] For this reason, NSAIDs are only available with a prescription in India.[109]
As with other drugs,
allergies to NSAIDs might exist. While many allergies are specific to one NSAID, up to 1 in 5 people may have unpredictable cross-reactive allergic responses to other NSAIDs as well.[111]
Immune response
Although small doses generally have little to no effect on the immune system, large doses of NSAIDs significantly suppress the production of immune cells.[112] As NSAIDs affect prostaglandins, they affect the production of most fast growing cells.[112] This includes immune cells.[112] Unlike
corticosteroids, they do not directly suppress the immune system and so their effect on the immune system is not immediately obvious.[112] They suppress the production of new immune cells, but leave existing immune cells functional.[112] Large doses slowly reduce the immune response as the immune cells are renewed at a much lower rate.[112] Causing a gradual reduction of the immune system, much slower and less noticeable than the immediate effect of Corticosteroids.[112] The effect significantly increases with dosage, in a nearly exponential rate.[112] Doubling of dose reduced cells by nearly four times.[112] Increasing dose by five times reduced cell counts to only a few percent of normal levels.[112] This is likely why the effect was not immediately obvious in low dose trials, as the effect is not apparent until much higher dosages are tested.[112]
Interactions
NSAIDs reduce kidney blood flow and thereby decrease the efficacy of
diuretics, and inhibit the elimination of
lithium and
methotrexate.[113]
NSAIDs may interfere and reduce effectiveness of
SSRI antidepressants through inhibiting
TNFα and
IFNγ, both of which are cytokine derivatives.[115][116] NSAIDs, when used in combination with SSRIs, increase the risk of adverse gastrointestinal effects.[117] NSAIDs, when used in combination with SSRIs, increase the risk of internal bleeding and brain hemorrhages.[118]
NSAIDs may reduce the effectiveness of
antibiotics. An
in-vitro study on cultured
bacteria found that adding NSAIDs to antibiotics reduced their effectiveness by around 20%.[120]
COX-1 is a constitutively expressed enzyme with a "house-keeping" role in regulating many normal physiological processes. One of these is in the
stomach lining, where prostaglandins serve a protective role, preventing the stomach
mucosa from being eroded by its own acid. COX-2 is an enzyme facultatively expressed in inflammation, and it is inhibition of COX-2 that produces the desirable effects of NSAIDs.[125]
When nonselective COX-1/COX-2 inhibitors (such as aspirin, ibuprofen, and naproxen) lower stomach prostaglandin levels,
ulcers of the stomach or
duodenum and internal
bleeding can result.[126] The discovery of COX-2 led to research to the development of selective COX-2 inhibiting drugs that do not cause gastric problems characteristic of older NSAIDs.[127]
NSAIDs have been studied in various assays to understand how they affect each of these enzymes. While the assays reveal differences, unfortunately, different assays provide differing ratios.[128]
Paracetamol (acetaminophen) is not considered an NSAID because it has little anti-inflammatory activity. It treats pain mainly by blocking COX-2 mostly in the central nervous system, but not much in the rest of the body.[15]
However, many aspects of the mechanism of action of NSAIDs remain unexplained, and for this reason, further COX pathways are hypothesized. The
COX-3 pathway was believed to fill some of this gap but recent findings make it appear unlikely that it plays any significant role in humans and alternative explanation models are proposed.[15]
NSAIDs are also used in the acute pain caused by
gout because they inhibit
urate crystal
phagocytosis besides inhibition of prostaglandin synthase.[132]
Antipyretic activity
NSAIDs have
antipyretic activity and can be used to treat fever.[133][134] Fever is caused by elevated levels of
prostaglandin E2 (PGE2), which alters the firing rate of neurons within the
hypothalamus that control thermoregulation.[133][135] Antipyretics work by inhibiting the enzyme COX, which causes the general inhibition of
prostanoid biosynthesis (PGE2) within the hypothalamus.[133][134] PGE2 signals to the hypothalamus to increase the body's thermal setpoint.[134][136]Ibuprofen has been shown more effective as an
antipyretic than
paracetamol (acetaminophen).[135][137]Arachidonic acid is the precursor substrate for cyclooxygenase leading to the production of prostaglandins F, D, and E.[138]
Classification
NSAIDs can be classified based on their chemical structure or mechanism of action. Older NSAIDs were known long before their mechanism of action was elucidated and were for this reason classified by chemical structure or origin. Newer substances are more often classified by mechanism of action.[139]
Most NSAIDs are
chiral molecules;
diclofenac and the
oxicams are exceptions. However, the majority are prepared as
racemic mixtures. Typically, only a single
enantiomer is pharmacologically active. For some drugs (typically profens), an
isomeraseenzymein vivo converts the inactive enantiomer into the active form, although its activity varies widely in individuals. This phenomenon is likely responsible for the poor correlation between NSAID efficacy and plasma concentration observed in older studies when specific analysis of the active enantiomer was not performed.[medical citation needed]
Ibuprofen and
ketoprofen are now available in single-enantiomer preparations (dexibuprofen and dexketoprofen), which purport to offer quicker onset and an improved side-effect profile.
Naproxen has always been marketed as the single active enantiomer.[medical citation needed]
Main practical differences
NSAIDs within a group tend to have similar characteristics and tolerability. There is little difference in clinical efficacy among the NSAIDs when used at equivalent doses.[151] Rather, differences among compounds usually relate to dosing regimens (related to the compound's
elimination half-life), route of administration, and tolerability profile.[medical citation needed]
Regarding adverse effects, selective
COX-2 inhibitors have lower risk of gastrointestinal bleeding.[151] With the exception of
naproxen, nonselective NSAIDs increase the risk of having a heart attack.[151] Some data also supports that the partially selective
nabumetone is less likely to cause gastrointestinal events.[151]
A consumer report noted that
ibuprofen, naproxen, and
salsalate are less expensive than other NSAIDs, and essentially as effective and safe when used appropriately to treat osteoarthritis and pain.[152]
Most nonsteroidal anti-inflammatory drugs are weak acids,[153] with a pKa of 3–5. They are absorbed well from the
stomach and intestinal mucosa. They are highly protein-bound in plasma (typically >95%), usually to
albumin, so that their
volume of distribution typically approximates to plasma volume. Most NSAIDs are metabolized in the
liver by
oxidation and conjugation to inactive metabolites that typically are excreted in the
urine, though some drugs are partially excreted in
bile. Metabolism may be abnormal in certain disease states, and accumulation may occur even with normal dosage.[medical citation needed]
Ibuprofen and diclofenac have short half-lives (2–3 hours). Some NSAIDs (typically oxicams) have very long half-lives (e.g. 20–60 hours).[medical citation needed]
History
It is widely believed that naturally occurring salicin in
willow trees and other plants was used by the ancients as a form of analgesic or anti-inflammatory drug,[154] but this story, although compelling, is not entirely true.[155][156] Hippocrates does not mention willow at all.[157]Dioscorides's De materia medica was arguably the most influential herbal from Roman to Medieval times but, if he mentions willow at all (there is doubt about the identity of 'Itea'), then he used the ashes, steeped in vinegar, as a treatment for corns,[158] which corresponds well with modern uses of
salicylic acid.
Willow bark (from trees of the
Salix genus) was widely known to be used as a medicine by multiple First Nations communities.[159] The bark would be chewed or steeped in water for its pain relieving and antipyretic effects. The effects are a result of the bark's salicin content. Meadowsweet, another plant to contain salicin, has strong roots in British folk medicine for the same maladies. Willow bark was first reported in Western science by Edward Stone in 1763 as a treatment for
ague (fever) according to the pseudoscientific
doctrine of signatures.[160]
In the body, salicin is turned into salicylic acid, which produces the antipyretic and analgesic effects that the plants are known for.
By 1897 the German chemist
Felix Hoffmann and the
Bayer company prompted a new age of pharmacology by converting salicylic acid into acetylsalicylic acid—named
aspirin by
Heinrich Dreser. Other NSAIDs like
ibuprofen were developed from the 1950s forward.[161]
In 2001, NSAIDs accounted for 70,000,000 prescriptions and 30billion
over-the-counter doses sold annually in the
United States.[46]
Veterinary use
Research supports the use of NSAIDs for the control of pain associated with veterinary procedures such as dehorning and castration of calves.[citation needed] The best effect is obtained by combining a short-term local anesthetic such as
lidocaine with an NSAID acting as a longer term analgesic.[citation needed] However, as different species have varying reactions to different medications in the NSAID family, little of the existing research data can be extrapolated to animal species other than those specifically studied, and the relevant government agency in one area sometimes prohibits uses approved in other jurisdictions.[citation needed]
In the United States,
meloxicam is approved for use only in canines, whereas (due to concerns about liver damage) it carries warnings against its use in cats[166][167] except for one-time use during surgery.[168] In spite of these warnings, meloxicam is frequently prescribed "off-label" for non-canine animals including cats and livestock species.[169] In other countries, for example
The European Union (EU), there is a label claim for use in cats.[170]
^Case JP (2001). "Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1: the older drugs". American Journal of Therapeutics. 8 (2): 123–143.
doi:
10.1097/00045391-200103000-00007.
PMID11304666.
^LeFanu J (2011). The Rise and Fall of Modern Medicine. Abacus. p. 34.
^Gøtzsche PC (March 1989). "Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis". Controlled Clinical Trials. 10 (1): 31–56.
doi:
10.1016/0197-2456(89)90017-2.
PMID2702836.
^Roelofs PD, Deyo RA, Koes BW, Scholten RJ, van Tulder MW (2008), "Cochrane Database of Systematic Reviews", The Cochrane Database of Systematic Reviews, 2008 (1): CD000396,
doi:
10.1002/14651858.CD000396.pub3,
PMC10220428,
PMID18253976
^Mutschler E (2013). Arzneimittelwirkungen [Pharmaceuticals] (in German). Wissenschaftliche Verlagsgesellschaft Stuttgart. p. 473.
ISBN978-3-8047-2898-1.
^"Drug Prescribing for Dentistry". www.SDCEP.org.uk. Scottish Dental Clinical Effectiveness Programme, NHS Education for Scotland. January 2016.
Archived from the original on 13 May 2020. Retrieved 4 February 2022.
^Wilson JA, Romagnuolo J, Byrne TK, Morgan K, Wilson FA (October 2006). "Predictors of endoscopic findings after Roux-en-Y gastric bypass". The American Journal of Gastroenterology. 101 (10): 2194–9.
doi:
10.1111/j.1572-0241.2006.00770.x.
PMID17032183.
S2CID29430849.
^
abKowalski ML, Asero R, Bavbek S, Blanca M, Blanca-Lopez N, Bochenek G, et al. (October 2013). "Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs". Allergy. 68 (10): 1219–32.
doi:
10.1111/all.12260.
PMID24117484.
S2CID32169451.
^
abStarSurg Collaborative (January 2017). "Safety of Nonsteroidal Anti-inflammatory Drugs in Major Gastrointestinal Surgery: A Prospective, Multicenter Cohort Study". World Journal of Surgery. 41 (1): 47–55.
doi:
10.1007/s00268-016-3727-3.
PMID27766396.
S2CID6581324.
^
abBhangu A, Singh P, Fitzgerald JE, Slesser A, Tekkis P (September 2014). "Postoperative nonsteroidal anti-inflammatory drugs and risk of anastomotic leak: meta-analysis of clinical and experimental studies". World Journal of Surgery. 38 (9): 2247–57.
doi:
10.1007/s00268-014-2531-1.
PMID24682313.
S2CID6771641.
^Baron JA, Sandler RS, Bresalier RS, Lanas A, Morton DG, Riddell R, et al. (November 2008). "Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial". The Lancet. 372 (9651): 1756–64.
doi:
10.1016/S0140-6736(08)61490-7.
PMID18922570.
S2CID39981292.
^Colebatch AN, Marks JL, Edwards CJ (November 2011). "Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis)". The Cochrane Database of Systematic Reviews (11): CD008872.
doi:
10.1002/14651858.CD008872.pub2.
PMID22071858.
^De Broe ME, Elseviers MM (February 1998). "Analgesic nephropathy". The New England Journal of Medicine. 338 (7): 446–52.
doi:
10.1056/NEJM199802123380707.
PMID9459649.
^
abKoren G, Florescu A, Costei AM, Boskovic R, Moretti ME (May 2006). "Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis". The Annals of Pharmacotherapy. 40 (5): 824–829.
doi:
10.1345/aph.1G428.
PMID16638921.
S2CID28057424.
^Ali MU, Usman M, Patel K (April 2020). "Effects of NSAID use on bone healing: A meta-analysis of retrospective case–control and cohort studies within clinical settings". Trauma. 22 (2): 94–111.
doi:
10.1177/1460408619886211.
ISSN1460-4086.
S2CID212748195.
^Ghosh N, Kolade OO, Shontz E, Rosenthal Y, Zuckerman JD, Bosco JA, et al. (December 2019). "Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Their Effect on Musculoskeletal Soft-Tissue Healing: A Scoping Review". JBJS Reviews. 7 (12): e4.
doi:
10.2106/JBJS.RVW.19.00055.
PMID31851037.
S2CID209407808.
^Ershad M, Ameer MA, Vearrier D (2022).
"Ibuprofen Toxicity". StatPearls. Treasure Island (FL): StatPearls Publishing.
PMID30252334.
Archived from the original on 27 October 2022. Retrieved 19 October 2022.
^"Dengue". United States Centers for Disease Control and Prevention. 28 March 2016.
Archived from the original on 24 March 2018. Retrieved 27 April 2018. Use acetaminophen. Do not take pain relievers that contain aspirin and ibuprofen (Advil), it may lead to a greater tendency to bleed.
^Auriel E, Regev K, Korczyn AD (2014). "Nonsteroidal anti-inflammatory drugs exposure and the central nervous system". Neurologic Aspects of Systemic Disease Part I. Handbook of Clinical Neurology. Vol. 119. pp. 577–84.
doi:
10.1016/B978-0-7020-4086-3.00038-2.
ISBN978-0-7020-4086-3.
PMID24365321.
^Woessner KM, Castells M (May 2013). "NSAID single-drug-induced reactions". Immunology and Allergy Clinics of North America. 33 (2): 237–49.
doi:
10.1016/j.iac.2012.12.002.
PMID23639711.
^
abcAronoff DM, Neilson EG (September 2001). "Antipyretics: mechanisms of action and clinical use in fever suppression". The American Journal of Medicine. 111 (4): 304–15.
doi:
10.1016/S0002-9343(01)00834-8.
PMID11566461.
^
abcKoeberle A, Werz O (2009). "Inhibitors of the microsomal prostaglandin E(2) synthase-1 as alternative to non steroidal anti-inflammatory drugs (NSAIDs)--a critical review". Current Medicinal Chemistry. 16 (32): 4274–96.
doi:
10.2174/092986709789578178.
PMID19754418.
^
abNabulsi M (October 2009). "Is combining or alternating antipyretic therapy more beneficial than monotherapy for febrile children?". BMJ. 339: b3540.
doi:
10.1136/bmj.b3540.
PMID19797346.
S2CID44269305.
^"Ibuprofen". DrugBank.
Archived from the original on 21 July 2014. Retrieved 29 January 2020.
^Consolidated List of products whose consumption or sale have been banned, withdrawn, severely restricted or not approved by Governments, United Nations, 2003, p. 123
link to 2005 ed
^Zhang L, Feng L, Jia Q, Xu J, Wang R, Wang Z, et al. (August 2011). "Effects of β-glucosidase hydrolyzed products of harpagide and harpagoside on cyclooxygenase-2 (COX-2) in vitro". Bioorganic & Medicinal Chemistry. 19 (16): 4882–6.
doi:
10.1016/j.bmc.2011.06.069.
PMID21775152.
^
abcdDean L (1 May 2011).
"Comparing NSAIDs". PubMed Clinical Q&A. National Center for Biotechnology Information.
Archived from the original on 28 July 2020. Retrieved 6 September 2017.
^
abHardman JG, Limbird LE, Gilman GA (1996). "Capítulo 27: Analgésicos-antipiréticos, antiinflamatorios y fármacos que se utilizan en el tratamiento de la gota.". Goodman & Gilman, las bases farmacológicas de la terapéutica (9 ed.). México: Ed. McGraw-Hill Interamericana.
ISBN978-0-07-026266-9.
^Metacam
Client Information SheetArchived 11 April 2011 at the
Wayback Machine, product description: "Non-steroidal anti-inflammatory drug for oral use in dogs only", and in the "What Is Metacam" section in bold-face type: "Do not use in cats.", January 2005.
^Rhodes L (September 2015). "Put a label (claim) on it: Getting non-surgical contraceptives approved for use in cats and dogs". Journal of Feline Medicine and Surgery. 17 (9): 783–9.
doi:
10.1177/1098612x15594993.
PMID26323803.
S2CID25045757.